Menlo Therapeutics, Inc.

/Menlo Therapeutics, Inc.

They are a late‑stage biopharmaceutical company focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis.

Symbol

Price Range
TBD

Anticipated Shares
7,000,000

Effective Date
January 25, 2018

Underwriters

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange